Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Uganda's efforts to combat the HIV/AIDS epidemic have made significant strides, yet crucial gaps remain, particularly in preventing mother-to-child transmission of the virus.

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...

Thirty-two-year-old Chen Wei-chi has been living with HIV since he was 18. Instead of letting it consume his life, he sought ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Marine, not her real name, was considering surgery to deal with intense pain. Three doctors refused to see her before a ...

The World Council of Churches has newly published a discussion document: Good News about HIV Treatment, Cure, and Healing: ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

However, for people like Anna Engomba, the arrival of new, life-saving medication ... of the limited available treatment options. While the numbers of people with HIV remains high, treatment ...

Alchemy, which sets up pharmacies in community clinics, said that it had raised $31 million from Andreessen Horowitz and ...